1st Speaker

Implementing Evidence-Based Cognitive-Behavioral Cancer Stress Management in Clinical Practice

Lisa Gudenkauf, Ph.D., L.P.

2nd Speaker

Utility of Urine Drug Testing in Outpatient Addiction Evaluations

Guillermo Leoz Callizo, M.D.

Introduction

1st Speaker
Dr. Lisa Gudenkauf is a second-year Clinical Health Psychology fellow at Mayo Clinic in Rochester, MN. She earned her Bachelor of Science degree from the University of Iowa in 2011 and her doctorate in Clinical Psychology from the University of Miami in 2016. She completed her internship in the Clinical Health Psychology program at the University of Wisconsin Hospital and Clinics in Madison, WI. Dr. Gudenkauf’s research has focused primarily on examining the efficacy of psychosocial interventions for enhancing coping among cancer survivors and implementing these interventions in clinical practice. She currently serves as co-Principal Investigator of a Department of Psychiatry & Psychology small grant-funded translational trial of cognitive-behavioral cancer stress management at Mayo Clinic.

2nd Speaker
Dr. Guillermo Leoz Callizo is an Addiction Psychiatry Fellow at Mayo Clinic’s Addiction Psychiatry program. He is originally from Asuncion, Paraguay. He graduated from medical school at the Universidad Nacional de Asuncion in Paraguay, summa cum laude. He then moved to New York City with his wife and completed his Psychiatry residency at Metropolitan Hospital Center (New York Medical College). Following his addiction fellowship he is continuing his career in Houston, Texas.

Learning Objectives

1st Speaker

1. Summarize the importance of assessing and addressing distress among cancer survivors.
2. Examine the evidence base for cognitive-behavioral stress management interventions.
3. Describe the implementation of a cognitive-behavioral cancer stress maangement program at mayo Clinic Rochester. 

2nd Speaker

1. Describe clinical issues in performing urine drug testing (UDT).
2. Describe the basic types of urine drug testing and when they should be used.
3. Describe the current evidence for the use of urine drug testing in addiction treatment.

Live webcast available at: http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live. Ethos will be implemented for all post presentation surveys. To document your attendance, please text the code given at the presentation to 507-200-3010. For questions, email rstpsychgr@mayo.edu.

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

APA
The Department of Psychiatry and Psychology at Mayo Clinic, Rochester, is approved by the American Psychological Association to sponsor continuing education credits for psychologists. The Department of Psychiatry and Psychology at Mayo Clinic, Rochester maintains responsibility for this program and its content.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

All participants MUST complete the evaluation in order to get CME or APA Credit.

1) Text the CODE announced at the session within 48 hours to (507) 200-3010
2) Login at ce.mayo.edu and go to My Account, My Courses, Registered Courses, click Session title and START to access the required Evaluation.
-or-
Click the START button on that session page.
3) Evaluation must be completed within 2 weeks.

Disclosure Summary
As a Jointly Accredited Provider by ACCME, ACPE, and ANCC, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Mark Frye, M.D. - Mayo Clinic

Grant Support: AssureRx, Janssen R&D, Myriad, Pfizer Consultant: Janssen R&D, Mitsubishi Tanabe Pharma Corp., Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel: American Physician Institute, CME Outfitters

No relevant financial relationship(s) with industry:
Kriti Gandhi, M.D., Allison Holgerson, Ph.D., Matej Markota, M.D., Charlene Nelson, Reem Shafi, M.B.B.S., Larua Suarez, M.D.

Speakers:  Lisa Gudenkauf, Ph.D., L.P. and Guillermo Leoz Callizo, M.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation: NONE